image
Healthcare - Drug Manufacturers - General - NYSE - CH
$ 103.06
-0.329 %
$ 202 B
Market Cap
17.99
P/E
1. INTRINSIC VALUE

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc.[ Read More ]

The intrinsic value of one NVS stock under the base case scenario is HIDDEN Compared to the current market price of 103 USD, Novartis AG is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NVS

image
FINANCIALS
46.7 B REVENUE
-9.97%
9.77 B OPERATING INCOME
6.22%
8.57 B NET INCOME
23.25%
14.5 B OPERATING CASH FLOW
1.56%
5.6 B INVESTING CASH FLOW
281.20%
-14.3 B FINANCING CASH FLOW
30.56%
13.2 B REVENUE
5.27%
3.63 B OPERATING INCOME
-7.66%
3.18 B NET INCOME
-1.88%
6.29 B OPERATING CASH FLOW
28.94%
-374 M INVESTING CASH FLOW
88.34%
-382 M FINANCING CASH FLOW
88.06%
Balance Sheet Decomposition Novartis AG
image
Current Assets 30.5 B
Cash & Short-Term Investments 14.4 B
Receivables 7.11 B
Other Current Assets 8.95 B
Non-Current Assets 69.5 B
Long-Term Investments 1.83 B
PP&E 10.9 B
Other Non-Current Assets 56.7 B
Current Liabilities 26.4 B
Accounts Payable 4.93 B
Short-Term Debt 6.31 B
Other Current Liabilities 15.2 B
Non-Current Liabilities 26.8 B
Long-Term Debt 20 B
Other Non-Current Liabilities 6.77 B
EFFICIENCY
Earnings Waterfall Novartis AG
image
Revenue 46.7 B
Cost Of Revenue 12.5 B
Gross Profit 34.2 B
Operating Expenses 24.9 B
Operating Income 9.77 B
Other Expenses 1.2 B
Net Income 8.57 B
RATIOS
73.27% GROSS MARGIN
73.27%
20.94% OPERATING MARGIN
20.94%
31.83% NET MARGIN
31.83%
31.82% ROE
31.82%
14.86% ROA
14.86%
12.89% ROIC
12.89%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Novartis AG
image
Net Income 8.57 B
Depreciation & Amortization 8.28 B
Capital Expenditures -2.75 B
Stock-Based Compensation 865 M
Change in Working Capital -369 M
Others -2.24 B
Free Cash Flow 11.7 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Novartis AG
image
Wall Street analysts predict an average 1-year price target for NVS of $117 , with forecasts ranging from a low of $108 to a high of $121 .
NVS Lowest Price Target Wall Street Target
108 USD 4.79%
NVS Average Price Target Wall Street Target
117 USD 13.28%
NVS Highest Price Target Wall Street Target
121 USD 17.41%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
3.78 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Novartis AG
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Here's Why Novartis (NVS) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 1 day ago
Down -10.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS) Novartis (NVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. zacks.com - 2 days ago
Schrodinger price target raised to $28 from $27 at Goldman Sachs Goldman Sachs raised the firm's price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company's Q3 results and announced deal with Novartis (NVS) involving both a research and expanded software utilization collaboration drove the stock higher, and while operating results from the quarter came in slightly below expectations, the management relayed confidence in the forward outlook for the balance of the year for the company's Software business, noting resiliency across large and mid-sized ACV accounts with increasing depth of utilization, the analyst tells investors in a research note. Schrodinger -0.165 (-0.74%) Novartis -1.08 (-1.03%) https://thefly.com - 3 days ago
Novartis (NVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Novartis (NVS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. zacks.com - 3 days ago
Down -9.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS) Novartis (NVS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com - 3 days ago
5 Low-Leverage Stocks to Buy Amid the Focus on Inflation Data The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You can buy JHG, CCB, NVS, APOG and IDCC. zacks.com - 3 days ago
Schrödinger's stock pops as it enters collaboration pact with Novartis worth up to $2.5 billion Schrödinger will receive $150 million upfront plus up to $2.3 billion in milestone and royalty payments. marketwatch.com - 5 days ago
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis NEW YORK--(BUSINESS WIRE)--Schrödinger today announced a multi-target collaboration and expanded software licensing agreement with Novartis. businesswire.com - 5 days ago
NVS or LLY: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Novartis (NVS) or Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com - 5 days ago
Is Novartis (NVS) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 week ago
Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant having nothing to fear from the end of patent protection on some drugs. reuters.com - 2 weeks ago
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights On Tuesday, Novartis AG NVS reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion. benzinga.com - 2 weeks ago
8. Profile Summary

Novartis AG NVS

image
COUNTRY CH
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 202 B
Dividend Yield 0.00%
Description Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Contact Lichtstrasse 35, Basel, 4056 https://www.novartis.com
IPO Date Nov. 7, 1996
Employees 76057
Officers Mr. Harry Kirsch Chief Financial Officer Paul Penepent Head of Group Financial Reporting and Accounting Dr. Steffen Lang Ph.D. President of Operations Dr. Robert Kowalski Pharm.D. Chief People & Organization Officer Dr. Vasant Narasimhan M.D. Chief Executive Officer Mr. Victor Bulto President of US Dr. Klaus Moosmayer Ph.D. Chief Ethics, Risk & Compliance Officer Dr. Patrick Horber M.D. President of International Ms. Karen L. Hale Chief Legal Officer Ms. Sloan Simpson Global Head of Investor Relations